Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(7 sites)
Singapore
National University Hospital (NUH), Singapore Singhealth Duke NUS blood cancer center, Singapore South Korea
Chonnam National University Hwasun Hospital, Hwasun Asan Medical Center, University of Ulsan College of Medicine, Seoul Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul Seoul National University Hospital, Seoul Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul